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Ameliorating antipsychotic-induced weight gain by betahistine:
mechanisms and clinical implications
Abstract
Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity and other
metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the histaminergic H1 receptor
(H1R) has been identified as one of the main contributors to weight gain/obesity side-effects. The effects and
mechanisms of betahistine (a histaminergic H1R agonist and H3 receptor antagonist) have been investigated
for ameliorating SGA-induced weight gain/obesity in both animal models and clinical trials. It has been
demonstrated that co-treatment with betahistine is effective in reducing weight gain, associated with
olanzapine in drug-naïve patients with schizophrenia, as well as in the animal models of both drug-naïve rats
and rats with chronic, repeated exposure to olanzapine. Betahistine co-treatment can reduce food intake and
increase the effect of thermogenesis in brown adipose tissue by modulating hypothalamic H1R-NPY-AMPKα
(NPY: neuropeptide Y; AMPKα: AMP-activated protein kinase α) pathways, and ameliorate olanzapine-
induced dyslipidaemia through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1:
Sterol regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) in the
liver. Although reduced locomotor activity was observed from antipsychotic treatment in rats, betahistine did
not affect locomotor activity. Importantly, betahistine co-treatment did not influence the effects of
antipsychotics on serotonergic receptors in the key brain regions for antipsychotic therapeutic efficacy.
However, betahistine co-treatment reverses the upregulated dopamine D2 binding caused by chronic
olanzapine administration, which may be beneficial in reducing D2 supersensitivity often observed in chronic
antipsychotic treatment. Therefore, these results provide solid evidence supporting further clinical trials in
treating antipsychotics-induced weight gain using betahistine in patients with schizophrenia and other mental
disorders.
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Second generation antipsychotic drugs (SGAs) cause substantial body weight gain/obesity 
and other metabolic side-effects such as dyslipidaemia. Their antagonistic affinity to the 
histaminergic H1 receptor (H1R) has been identified as one of the main contributors to weight 
gain/obesity side-effects. The effects and mechanisms of betahistine (a histaminergic H1R 
agonist and H3 receptor antagonist) have been investigated for ameliorating SGA-induced 
weight gain/obesity in both animal models and clinical trials. It has been demonstrated that 
co-treatment with betahistine is effective in reducing weight gain, associated with olanzapine 
in drug-naïve patients with schizophrenia, as well as in the animal models of both drug-naïve 
rats and rats with chronic, repeated exposure to olanzapine. Betahistine co-treatment can 
reduce food intake and increase the effect of thermogenesis in brown adipose tissue by 
modulating hypothalamic H1R-NPY-AMPKα (NPY: neuropeptide Y; AMPKα: AMP-
activated protein kinase α) pathways, and ameliorate olanzapine-induced dyslipidaemia 
through modulation of AMPKα-SREBP-1-PPARα-dependent pathways (SREBP-1: Sterol 
regulatory element binding protein 1; PPARα: Peroxisome proliferator-activated receptor-α) 
in the liver. Although reduced locomotor activity was observed from antipsychotic treatment 
in rats, betahistine did not affect locomotor activity. Importantly, betahistine co-treatment did 
not influence the effects of antipsychotics on serotonergic receptors in the key brain regions 
for antipsychotic therapeutic efficacy. However, betahistine co-treatment reverses the 
upregulated dopamine D2 binding caused by chronic olanzapine administration, which may 
be beneficial in reducing D2 supersensitivity often observed in chronic antipsychotic 
treatment. Therefore, these results provide solid evidence supporting further clinical trials in 
treating antipsychotics-induced weight gain using betahistine in patients with schizophrenia 
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Short Bullet Points 
1. Betahistine co-treatment ameliorates olanzapine-induced weight gain through 
hypothalamic H1R- AMPKα, NPY pathways. 
 
2. Betahistine co-treatment reduces olanzapine-induced dyslipidaemia via AMPKα-
SREBP-1-PPARα-dependent pathways in the liver. 
 
3. Co-treatment with betahistine does not affect the therapeutic efficacy of 
antipsychotics.                  
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1. Introduction  
Second generation antipsychotic drugs (SGAs), also called “atypical antipsychotics”, are 
currently the first line of treatment for schizophrenia and other serious mental disorders, with 
fewer extrapyramidal symptoms (EPS) side-effects at clinically effective doses compared 
with first generation antipsychotics (FGAs) [1-4]. However, SGAs such as olanzapine and 
clozapine are associated with much more severe weight gain/obesity side-effects, and with 
other common metabolic disorders such as dyslipidaemia, gluco-metabolic abnormalities, 
insulin resistance, and even type II diabetes [5-7]. They are currently of great interest to 
clinicians due to their widespread use in clinics [8-10]. Besides the dopaminergic D2 receptor 
(D2R), accumulated evidence has demonstrated that SGAs affect a wide range of G-protein-
coupled receptors including serotonergic 5-HT2A (5-HT2AR), histaminergic H1 (H1R), 
serotonergic 5-HT2C (5-HT2CR), and muscarinic M3 (M3R) receptors, contributing to weight 
gain/obesity and other metabolic side-effects [11]. Among them, H1R and 5-HT2CR 
antagonism have been identified as the main indicators for predicting weight gain-induced by 
SGAs [12-14].  
 
Previous studies have reported various intervention strategies to reduce SGA-induced weight 
gain [15-17]. Regarding pharmacological interventions, a number of drugs have been trialled 
with some success in partially ameliorating SGA-induced weight gain side-effects. A meta-
analysis study examined 25 pharmacologic weight loss intervention trials (n=1221) and 
revealed that amantadine, metformin, reboxetine, sibutramine and topiramate were effective 
in partially reducing SGA-induced weight gain [18]. Another meta-analysis of 32 placebo-
controlled pharmacologic intervention trials involving 1482 subjects suggested that 
metformin had the most promising effect on weight loss, followed by fenfluramine, 
sibutramine, topiramate, and reboxetine [19]. Other clinical trials also showed a similar effect 
of metformin in attenuating SGA-induced weight gain [18, 20-23]. A recent study reported 
that both metformin and berberine treatment did not affect food intake, but significantly 
prevented olanzapine-induced brown fat loss [24]. The same author further found that 
uncoupled protein-1 (UCP1) expression was significantly increased after co-treatment of 
metformin and olanzapine, compared with olanzapine only treatment [24]. In addition, 
metformin and rosiglitazone can also reduce glucose intolerance and insulin resistance in 
patients treated with SGAs [25, 26]. The potential of zoisamide, sibutramine and topiramate 
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have also been addressed as adjuvant treatments for weight loss of schizophrenic patients 
treated with SGAs [27-29, 17, 30-32]. 
 
However, to date, these pharmacological intervention studies were not based on the 
mechanisms of SGA-induced weight gain, particularly considering H1R and 5-HT2CR as the 
key contributors. Therefore, it is important to investigate the potential for targeting these 
receptors to control SGA-induced weight gain. In view that histaminergic system could be a 
target for preventing obesity [33],  this paper reviewed recent reports from both animal and 
clinical studies on exploring the potential of betahistine (an H1R agonist and H3 receptor (H3R) 
antagonist) to ameliorate SGA-induced weight gain/obesity, and more importantly 
summarized recent progresses in the underlying mechanisms for this preventing effects by 
betahistine co-treatment.  
 
2. Materials and Methods 
The systematic electronic reference search for this review paper was performed using the 
Medline and ScienceDirect databases (until October 2015). Key words included atypical 
antipsychotic, second generation antipsychotics, individual drug names such as olanzapine,  
risperidone, aripiprazole, quetiapine, haloperidol and ziprasidone, histamine, histamine 
receptor, H1 receptor, H3 receptor, serotonin receptor, 5HT2A receptor, 5-HT2C receptor, 
AMPK, betahistine, intervention, co-treatment, lipid activity, rats, mice, clinical trial, as well 
as their cross-references with weight gain, obesity, food intake and energy expenditure. In 
addition, the reference list of all papers identified was reviewed. 
 
3. The role of histamine neurotransmission in SGA-induced weight gain  
3.1 The role of histamine neurotransmission 
Histamine neurons originate from the tuberomammillary nucleus (TMN) of the posterior 
hypothalamus (which receives very dense orexin innervations originating from the lateral 
hypothalamus) and project to all brain regions including the hypothalamus itself [34, 35]. 
Since histamine cannot cross the blood-brain barrier, it is synthesised in situ in the brain from 
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the precursor amino acid, L-histidine and catalysed by the rate-limiting enzyme histidine 
decarboxylase (HDC) [36]. Histamine exerts its actions via the specific histaminergic 
receptors, which have been classified into the H1, H2, H3 and H4 receptor subtypes [37, 38]. 
All are G-protein-coupled receptors and widely expressed throughout the body. In the central 
nervous system (CNS), H1Rs are mainly located postsynaptically and are found especially in 
the hypothalamus, cerebral cortex and limbic system [37, 39], where they are well 
documented as involved in the regulation of body weight and food intake. H2 receptors are 
also mainly located postsynaptically and are expressed in the hippocampus, amygdala and 
basal ganglia [37]. H3 receptors are exclusively located presynaptically and found in the 
nucleus accumbens (NAc), striatum, basal ganglia, and hypothalamus, and regulate histamine 
production and release [40, 37]. H4 receptors are expressed in the hypothalamus and spinal 
cord [41].  
 
The neurotransmitter histamine plays a crucial role in the regulation of a wide range of 
behavioural and physiological functions in humans and animals, such as appetite, drinking, 
sleep, wakefulness, locomotor activity, learning and memory [37, 34, 42, 33]. In particular, 
histamine has been implicated in the regulation of energy homeostasis [12, 43, 44]. In other 
words, elevated hypothalamic histamine signalling contributed to decreased food intake and 
decreased body weight gain [45-47, 35], while reduction in histamine levels was associated 
with increased body weight gain and food intake [37, 42]. Histamine knockout mice 
predominantly exhibited obesity with increased visceral adiposity, hyperlipidaemia and 
decreased glucose tolerance [48, 36, 49]. It has also been reported that SGAs such as 
olanzapine can directly modulate histaminergic neurotransmission in the hypothalamus, 
which correlated with the regulation of feeding behaviour in rats [50]. Therefore, the 
histaminergic system could be a target for preventing obesity and other metabolic disorders 
[33]. 
 
3.2 H1R, H3R and SGA-induced weight gain 
Histaminergic H1Rs are highly expressed in the hypothalamic arcuate nucleus (Arc), 
ventromedial hypothalamic nucleus (VMH) and paraventricular nucleus (PVN) [51], and are 
involved in the regulation of food intake and energy expenditure [35, 52]. It has been 
reported that H1R antagonists play a crucial role in increasing appetite and obesity 
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development [12, 53], which were also observed in H1R knockout (KO) mice [51, 54]. 
Moreover, deprivation of food predominantly led to activation of H1R expression in the 
hypothalamic Arc [13, 55]. It was confirmed that Intracerebroventricular (ICV) injection of 
the H1R agonist, 2-(3-trifluoromethylphenyl)histamine (FMPH) inhibited food intake [56].  
 
H1R antagonist properties have been identified as playing a significant role in the 
development of SGA-induced body weight gain/obesity side-effects (approximately 
Clozapine = Olanzapine > Quetiapine > Risperidone > Haloperidol > Ziprasidone = 
Aripiprazole) [57, 58, 14, 59]. In particular, H1R blockade is recognised as a predominant 
target for SGA-induced weight gain compared with other receptors [4, 60, 61]. Several 
animal studies found that olanzapine could modulate histaminergic neurotransmission for the 
regulation of food intake and weight gain in rats [62, 56, 63]. Olanzapine treatment 
upregulated mRNA expression and protein levels of hypothalamic H1R, which was correlated 
with hyperphagia and weight gain induced by olanzapine [56, 64, 65]. Similarly, clinical 
studies demonstrated patients treated with antipsychotics showed a significant correlation 
between the genetic variants of H1R (rs346074 – rs346070), BMI (body mass index) and 
obesity [66, 67].  
 
Since histamine cannot pass the blood-brain barrier, direct peripheral H1R antagonism by 
SGA treatment may also contribute to the obesity side-effects [13, 56, 64]. The H1R 
antagonistic affinity of SGAs is significantly correlated not only with increased body weight 
and adiposity, but also with insulin-resistance in schizophrenia patients [68, 60, 69]. Other 
antihistamine drugs such as loratadine and cyproheptadine are also associated with increased 
body weight and hyperplasia [70-73]. Furthermore, the H1R antagonistic affinity of SGAs 
contributes to fat accumulation via downregulation of lipolysis, while upregulating 
lipogenesis in white adipose tissue [74-77].  
 
In addition to H1R, the histaminergic H3R is another significant target for regulating food 
intake and is highly expressed in the TMN of the hypothalamus [12, 78, 79]. Furthermore, H3 
heteroreceptors are also located on non-histaminergic neurons, regulating release of 
neurotransmitters such as acetylcholine, serotonin and dopamine, and may also be involved in 
food intake regulation [78, 42, 80, 81]. However, SGAs maintain a very weak antagonistic 
potency at histaminergic H3Rs in the brain [82, 83]. As a result, H3R may play an indirect 
role in regulating the weight gain/obesity side-effects induced by SGAs. For example, it is 
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possible that SGAs can block postsynaptic H1Rs, which may then lead to accumulation of 
histamine in the synaptic cleft [12] (summarised in Figure 1). Since the release and synthesis 
of histamine are regulated by presynaptic H3 autoreceptors [84, 78], the accumulated 
histamine then activates the pre-synaptic H3R slowing the synthesis and secretion of 
histamine and heightening feeding behaviour [85, 12, 78, 80]. On the other hand, it was found 
that intraperitoneal injection of risperidone immediately increased hypothalamic histamine 
release, that was regulated by  H3R [86].  
 
3.3 The role of hypothalamic H1R-AMPK signalling in SGA-induced weight gain  
Hypothalamic AMP-activated protein kinase (AMPK) is highly expressed in the Arc, PVN, 
VMH and Lateral hypothalamus (LH) of the hypothalamus [63, 87, 88]. It has been suggested 
that AMPK activity could be inhibited by histamine in hypothalamic tissue slices, while it is 
activated by H1R antagonist triprolidine in both hypothalamic tissue slices and the 
hypothalamus of knock-out mice [63]. In addition, it is important to note that hyperphagia in 
diet-induced obese animals is attributed to the effect of hypothalamic AMPK signalling [89]. 
Kahn and colleagues showed that AMPK activity in the hypothalamic Arc and PVN was 
inhibited by anorexigenic leptin and augmented by orexigenic Agouti-related protein (AgRP) 
[90]. Hypothalamic AMPK is also involved in feeding regulation and food intake by 
regulating the AMPK-ACC-Malonyl-CoA-CPT1 axis (ACC: acetyl-CoA carboxylase; CPT1: 
carnitine palmitoyltransferase 1) [91-94]. A study using the CT1-1 cell line reported that the 
protein level of phosphor-AMPK (pAMPK) is activated by the H1R antagonist 
chlorpheniramine, while it is blocked by histamine [95].  
 
It has been found that olanzapine and clozapine activated hypothalamic AMPK by blocking 
H1Rs to increase food intake and body weight gain [63, 96, 97]. In hypothalamic tissue slices, 
the level of pAMPK can be enhanced markedly by olanzapine, which indicates that the 
weight gain/obesity side-effects associated with olanzapine is mediated by activation of 
hypothalamic AMPK linked to blockade of the histaminergic H1R [63]. Further in vivo 
studies in a rat model showed that the pAMPK level was upregulated by olanzapine 
administration correlated with changes in weight gain [56, 64, 65]. Additionally, 
administration of olanzapine by acute ICV infusion increased hypothalamic pAMPK 
expression [98, 99]. Therefore, besides H1R itself, its downstream AMPK signals are also 
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valuable targets for treating SGA-induced weight gain/obesity side-effects [12, 13] 
(summarized in Figure 1). 
 
4. The role of hypothalamic neuropeptide and regulation of energy 
homeostasis in SGA-induced weight gain 
SGA-induced weight gain is associated with alterations to the neuroendocrine network that 
controls appetite, food intake and satiety [7, 67]. As mentioned above, the hypothalamic Arc 
plays a crucial role in appetite and energy homeostasis via activation of 2 distinct neural 
populations: (1) anabolic/orexigenic neurons expressing Neuropeptide Y (NPY) and AgRP, 
and (2) catabolic/anorexigenic neurons expressing pro-opiomelanocortin (POMC) and 
cocaine-and amphetamine-regulated transcript (CART) [100-102], which are involved in the 
regulation of SGA-induced weight gain. 
 
4.1 The role of NPY and AgRP in SGA-induced weight gain 
In the CNS, NPY is mainly synthesized in the hypothalamus, brainstem and anterior pituitary 
[103]. As the biomarker for obesity, NPY is a major mediator in promoting energy storage 
[104], which regulates food intake, fat deposition and metabolism via various G-protein-
coupled NPY receptors including NPY receptor subtype 1, 2, and 5 [105, 106]. For example, 
the NPY receptor sub-type 5 antagonist, Velneperit, has been identified in clinical tests as a 
potential anti-obesity drug [107, 108]. It has been reported that injection of NPY into the 
PVN repeatedly led to sustained hyperphagia, body weight gain and fat mass accumulation 
[109, 110]. In addition, synthesis and secretion of Arc NPY resulted in response to energy 
deficiency and greater metabolic need such as increased exercise, cold and pregnancy [111-
113]. Moreover, the Arc NPY neurons play a role in integrating peripheral energy signals, 
such as blood glucose concentration, ghrelin, leptin and insulin [114, 115]. AgRP is 
synthesised exclusively in the Arc that projects to adjacent hypothalamic regions such as the 
PVN, DMN and LH [116, 110]. The major function of AgRP is to stimulate feeding by 
antagonising melanocortins at the MC3R (melanocortin 3 receptor) and MC4R (melanocortin 
4 receptor) in the hypothalamus [117-120] (summarised in Figure 1). Polymorphism of the 
AgRP gene is associated with inherited leanness in humans [121]. Similar to NPY, both 
leptin deficiency (ob/ob) and leptin receptor mutation (db/db) resulted in overexpression of 
14 
 
AgRP in the Arc of mice [122, 118, 123], which has also arisen from fasting in rats and mice 
[124]. AgRP is sustained for up to a week after a single ICV injection, compared with the 
effects of NPY which are sustained over hours [125, 126]. Selective ablation of NPY/AgRP-
expressing nuclei in adult mice resulted in acute reduction of feeding [127].  
 
The effects of SGAs on expression of NPY and AgRP have been investigated in previous 
studies. Fernø and colleagues demonstrated that short-term exposure to olanzapine (6 days) 
resulted in upregulated NPY and AgRP expressions in the Arc of both rats fed ad libitum and 
pair-fed rats [98]. Olanzapine upregulated NPY mRNA expression in a dosage dependent 
manner in the hypothalamic Arc [128]. Furthermore, increased hypothalamic NPY and AgRP 
expression were also observed by the study using ICV administration of olanzapine [98, 99]. 
It has also been reported that the NPY level was upregulated in short (7 days) and mid-term 
(15 days) olanzapine treatment in rats [129]. Ak and colleagues also reported that the plasma 
NPY level was attenuated in first attack psychotic male patients treated with olanzapine [100], 
while quetiapine increased the NPY level in cerebrospinal fluid from schizophrenia patients 
[130]; these changes in NPY level were associated with SGA-induced weight gain. It has also 
been reported that clozapine enhanced hypothalamic NPY expression in rats [131, 60] 
(summarised in Figure 1). The association between AgRP, fat mass and appetite have been 
examined and were found to be disrupted in olanzapine-treated patients, but not in patients 
treated with ziprasidone [132]. Although an early study by Ruano and colleagues reported 
that a polymorphism (rs1468271) in the NPY gene had no association with body weight gain 
in patients treated with olanzapine and risperidone [133], a recent study by Tiwari and 
colleagues suggested a significant association between the SNPs rs16147, rs5573, and rs5574 
in NPY and weight gain in clozapine and olanzapine-treated patients [134]. The same authors 
also revealed an association of rs6837793, near NPY5R, with the weight gain profile in 
patients treated with risperidone, which supported the role of the NPY system in SGA-
induced weight gain. Furthermore, it has been reported that there was significant upregulation 
of NPY expression in H1R-knockout and HDC (the neuronal histamine-synthesising 
enzyme)-knockout mice compared to wild mice [135]. Therefore, SGAs may regulate NPY 




4.2 The role of POMC and CART in SGA-induced weight gain 
POMC is synthesized from the 285-amino-acid-long polypeptide precursor, and produces 
peptide hormones including β-endorphins and melanocortin [118, 136, 137]. There are 
several subtypes of the melanocortin peptides, such as adrenocorticotrophin (ACTH) and 
alpha-melanocyte-stimulating hormone (α-MSH), which act at G-protein-coupled 
melanocortin receptors such as the MC1-5 receptors [118, 138, 139]. In the brain, POMC is 
mainly expressed in the Arc [138, 140], and projects to various regions of the hypothalamus 
[118, 141]. Certain POMC gene mutations may contribute to obesity in healthy human 
populations [142, 143], while mouse knockout for POMC also shows the obese phenotype 
[138, 144]. POMC mRNA expression is reduced by food restriction, while it is increased in 
overfed rats [145, 146]. Importantly, activation of POMC neurons is regulated by the binding 
of 5-HT to 5-HT2R [100, 147] (summarised in Figure 1). Additionally, POMC expression in 
the Arc is also regulated by the dopaminergic system via D2R [148, 149]. CART is a peptide 
(first isolated from the ovine hypothalamus), and is widely distributed throughout the central 
and peripheral nervous systems [150, 151]. CART protein is encoded by the CARTPT gene, 
which functions in feeding, reward, stress and pain transmissions [152, 153]. Similar to 
POMC, CART also downregulates food intake and body weight [154, 155]; a previous study 
revealed that CART has an effect on neuronal activities (including the hypothalamic VMH 
and PVN), which are involved in the neuroplasticity of hypothalamic feeding circuits [156]. 
Furthermore, CART interacts with other important mediators such as the cannabinoid CB1 
receptor, insulin and leptin, involved in the regulation of feeding [157, 158, 150]. On the 
other hand, ICV administration of CART was accompanied by a decrease in plasma insulin 
and leptin levels and an increase in lipid oxidation, which limits fat storage [159]. 
 
In terms of the effect of SGAs on expression of POMC and CART, it was shown that 
olanzapine treatment resulted in attenuation of POMC but not CART expression in the 
hypothalamus of rats [98, 65, 160, 128, 129]. Ak and colleagues also reported that the plasma 
POMC level was elevated in first attack psychotic male patients treated with olanzapine, but 
no changes in plasma CART level were observed [100]. It should be noted that olanzapine 
suppresses POMC expression by blocking 5-HT2CR, and indirectly blocking 5-HT1B 
receptors (5-HT1BR), while that suppression is abolished by GABA (gamma-aminobutyric 
acid) neurons [161] (summarised in Figure 1). However, a recent genetic study reported that 
neither the POMC single nucleotide polymorphisms (SNPs) (rs6713532, rs1047521, 
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rs3754860) nor the CART SNP (rs10515115, rs3763153, rs3857384, rs11575893, 
rs16871471) gene variants was associated with weight gain in chronic schizophrenia patients 
treated with SGAs [162]. On the other hand, a genetic polymorphism study suggested that 
MC4R is relevant to SGA-induced weight gain and related metabolic disorders [163].  
 
5. Co-treatment with betahistine to control SGA-induced weight gain 
5.1 Betahistine and its safety profile  
As reviewed above, the antagonistic property of histaminergic H1R is the major contributor to 
SGA-induced weight gain side-effects; therefore, there is great potential for controlling that 
weight gain by targeting H1R. The question is therefore whether an H1R agonist could be 
used to prevent and treat SGA-induced obesity. One candidate is FMPH, a selective H1R 
agonist, which has been shown to reverse SGA-induced hyperphagia after ICV injection [56]. 
Unfortunately, it is unable to cross the blood-brain barrier [164]. In fact, over the past 30 
years, a number of histaminergic ligands have been tested on their effects on food intake and 
body weight, however to-date there is no highly selective and orally deliverable H1R agonist 
on the market [reviewed by Provensi et al. [33]]. Another candidate is betahistine (C8H12N2), 
which can cross the blood-brain barrier and acts centrally by enhancing histamine 
neurotransmission in the tuberomamillary nuclei of the posterior hypothalamus [167]. 
Betahistine acts as a modulator of the histaminergic system and has both H1R-agonistic and 
H3R-antagonistic properties in the brain [74,168,169]. Under normal conditions, histamine 
may activate H1R on the hypothalamic neurons, leading to a decrease in food intake, while 
SGAs such as olanzapine block histaminergic H1R on the hypothalamic neurons causing an 
increase in food intake. As an H1R agonist, betahistine can directly activate H1R and may 
compete with olanzapine for binding to H1R, therefore reducing the H1R antagonist property 
of olanzapine. On the other hand, betahistine, as an H3R auto receptor antagonist, increases 
histamine release by blocking presynaptic H3R, which may augment its direct agonistic 
effects on H1R, and reduce weight gain [170]. 
 
It is worth noting that betahistine is readily available in clinics, has a high safety profile (only 
1:100000 reported adverse drug reactions), and has been used to treat more than 130 million 
patients suffering vestibular disorders such as vertigo and dizziness since the 1970s [165, 
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166]. It has been trialled as an anti-obesity drug in clinical trials. A randomised, double-blind 
placebo-controlled trial reported that 32 mg/day treatment of betahistine in 20 obese female 
subjects for 28 days resulted in 1.1% weight loss, compared to 0.6% weight gain in the 
placebo group [167]. Barak and colleagues also reported that 12 weeks’ treatment of 
betahistine (16-48 mg/kg) in 281 adults led to significant weight loss in the subgroup of non-
Hispanic women ≤50 years old with 48 mg/day betahistine treatment [167].  
 
5.2 Animal trials in betahistine intervention for reducing weight gain in drug naïve or 
chronic/repeated olanzapine treatment rat models  
Several animal studies have reported the effects of co-treatment of betahistine with 
olanzapine on reducing SGA-induced weight gain. Interestingly, the combined histaminergic 
H1R/H3R action of betahistine has been proven to be efficient in increasing satiety and 
reducing the desire to eat fatty foods in rats [168] (Table 1). Using the established rat model 
of olanzapine-induced weight gain, it was found that after short-term (2 weeks) treatment, 
drug naïve rats treated solely with olanzapine (1 mg/kg, t.i.d.) exhibited significant body 
weight gain and increased food intake (all p<0.001). However, betahistine only (2.67 mg/kg, 
t.i.d.) treatment had no effect on weight gain and food intake. Importantly, the O+B co-
treatment group exhibited significantly reduced feeding efficiency and body weight (~50% 
net decrease) compared to the olanzapine only-treated group (p=0.015) in drug-naïve rats 
[169] (Figure 2A). Olanzapine treatment also increased white fat mass, but had no effect on 
water intake [169]. Furthermore, olanzapine reduced locomotor activity of rats, which was 
significantly correlated with weight gain. These results suggested that reduced activity 
partially contributed to the weight gain side-effect induced by olanzapine. However, co-
treatment with betahistine cannot improve locomotor activities decreased by olanzapine. This 
finding may be one possible explanation of why betahistine can only partially improve 
olanzapine-induced weight gain [169] (Table 1).  
 
It is worth noting that clinical patients suffering with schizophrenia, bipolar disease and other 
mental disorders often face chronic, even life-time, treatment with antipsychotic drugs [165]. 
Since betahistine has a high safety profile and low adverse drug reaction, it is essential to 
investigate the effectiveness of betahistine in prevention of weight gain and obesity following 
chronic antipsychotic treatment in schizophrenia and other mental disorders. On the other 
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hand, it is well known that antipsychotics cause a significant body weight gain not only in 
drug-naïve patients, but also in chronic patients who usually have already had previous 
antipsychotic exposure [6, 65, 170]. In order to investigate whether chronic co-treatment of 
O+B would have similar weight-attenuating effects, the effect of co-treatment with 
betahistine was trialled in a rat model with repeated and chronic exposure to olanzapine [65]. 
It is interesting that in a chronic rat model, the significant body weight gain induced by 
olanzapine-treatment could be reversed following drug withdrawal; however weight gain was 
resumed after re-introducing olanzapine treatment (Figure 3A). It was shown that 6 week co-
treatment of olanzapine (1 mg/kg, t.i.d.) and betahistine (9.6 mg/kg, t.i.d.) significantly 
decreased (~51.4%) olanzapine-induced weight gain in rats with repeated SGA exposure. 
Furthermore, co-treatment also reduced feeding efficiency, liver and fat mass [65]. In 
addition, olanzapine-treated rats significantly increased inguinal fat (p<0.001), and periovary, 
mesentery fat (p<0.05) compared to controls (Table 1). In addition, a recent study found that 
chronic olanzapine treatment caused a significant upregulation of the circulating non-
esterified fatty acid (NEFA), triglyceride (TG) and hepatic lipid accumulation without 
altering cholesterol synthesis in rats, while betahistine co-treatment significantly reversed 
olanzapine-induced plasma TG and circulating NEFA [75]. Overall, the studies provided 
solid preclinical data for preventing/treating SGA-induced weight gain/dyslipidaemia by 
betahistine treatment, which provides strong support for further clinical trials to improve 
SGA (olanzapine) induced obesity and its related metabolic disorders using betahistine co-
treatment. 
 
5.3 Clinical trials for co-treatment of betahistine and olanzapine for reducing SGA-
induced weight gain/obesity  
Two clinical studies investigated the effect of betahistine treatment on weight loss in obese 
(otherwise healthy) subjects. Barak and colleagues conducted a multicentre randomized, 
placebo-controlled weight loss trial using betahistine (16, 32, 48 mg/day) in 281 obese adults 
for a 12-week treatment [171]. The overall results revealed that betahistine did not induce 
significant weight loss in obese participants at the above dosages, while the prevalence of 
adverse events was low. However, further subgroup analysis revealed that the non-Hispanics 
women ≤ 50 years old, treated by betahistine (48 mg/day) lost ~4.24 kg body weight, 
compared with the placebo group (~1.65 kg) (p=0.005) [171] (Table 1). Another randomized 
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placebo-controlled double-blind trial reported that 24 hours treatment of betahistine (48, 96, 
or 144 mg/day) had no effect on food intake or appetites [172], suggesting that long term 
administration  may be the essential factor to reveal the effect of betahistine on energy intake 
[172] (Table 1).  
 
There have been several clinical studies investigating the effects of betahistine co-treatment 
in reducing SGA-induced weight gain/obesity in schizophrenia patients. A small clinical trial 
(in three first-episode schizophrenia patients) found that betahistine (48 mg t.i.d.) was able to 
prevent significant weight gain caused by olanzapine treatment (10 mg/day) in a 6 weeks’ 
trial of co-treatment with O+B [173]. In detail, an increase in weight during the initial 2 
weeks was observed, followed by no additional weight gain (2 patients) or a minor reduction 
of body weight (one patient) from week 3 to 6. Overall, no subject gained 7% of baseline 
weight (a cut-off for clinically significant weight gain) [173] (Table 1). Hence, these results 
indicated a possible attenuating effect of betahistine on olanzapine-induced weight gain in 
schizophrenia patients.  
 
A later clinical trial with a double-blind placebo-controlled randomized design reported that 
co-administration with olanzapine, betahistine (48 mg/kg, t.i.d.) and reboxetine (4 mg b.i.d.) 
(a selective norepinephrine reuptake inhibitor) for 6 weeks in first episode schizophrenia 
patients resulted in significantly and clinically attenuated weight gain compared with 
olanzapine-only treatment (2.02±2.37 and 4.77±3.16kg, respectively, p=0.006) [174]. The 
corresponding increase in BMI was 0.65±0.75 in the olanzapine/reboxetine/betahistine group 
and 1.53±0.99 kg/m2 in the olanzapine/placebo group (p=0.008) [174] (Table 1). Importantly, 
there was complementary action in the CNS pathway in combination treatment with 
betahistine, reboxetine and olanzapine, namely, the weight attenuating effect of this 
combination was two-fold larger than reboxetine only combination (2.75 kg vs. 1.46 kg) [175, 
174].  
 
Another double-blind study demonstrated that 48 healthy women were treated with one week 
of betahistine (144 mg/day) or matching placebo, followed by olanzapine administration (7.5 
or 10 mg/day) for 3 weeks [176]. The result illustrated that the average weight gain in 
betahistine and placebo groups was 1.2 and 1.9 kg, respectively (p=0.0489), while 52% of the 
placebo group gained more than 2.0 kg, compared with only 23% in the treatment group 
(p=0.043) [176] (Table 1). The most recent clinical trial is in progress in evaluating the 
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effects of betahistine on reversing SGA-induced weight gain in adolescents and young adults; 
40 individuals with a diagnosis of schizophrenia or other mental disorders aged from 12-18, 
who have been treated with clozapine, olanzapine, risperidone, or  quetiapine for 6 weeks and 
with at least 2% weight gain will be recruited for this trial [177] (Table 1).  
 
Overall, betahistine co-treatment has shown clinically meaningful attenuation of olanzapine-
induced weight gain without changing the therapeutic effect of these antipsychotics. These 
clinical findings correspond with the results of animal studies, in which it was demonstrated 
that the co-treatment with betahistine partially reduced olanzapine-induced weight gain side-
effects [169]. It is worthy to note that histaminergic modulation may counterbalance drug-
induced overfeeding and weight gain, however it may be ineffective when there is no drug-
dependent alteration as showed in clinical trials in obese (otherwise health) subjects [172, 
171]. Therefore, it is not clear whether it could be useful as a weight-loss medication in obese 
non-medicated people. 
 
6. The mechanisms underlying betahistine in reducing antipsychotic-
induced weight gain 
As discussed above, SGA-induced weight gain may be addressed through the upregulation of 
hypothalamic H1R-AMPKα signalling, and NPY levels, accompanied by downregulation of 
POMC mRNA expression (summarised in Figure 1) [12, 98, 178, 63-65, 179, 160, 97, 129]. 
Additionally, it was also revealed that the expression of BAT UCP1 and PGC-1α protein 
levels (biomarkers of thermogenesis) is reduced by chronic olanzapine treatment [65, 180]. 
These results both confirmed that decreased energy expenditure and increased food 
intake/feeding efficiency contributed to increased weight gain induced by chronic olanzapine 
treatment [65, 180]. 
 
Several studies systematically investigated the mechanisms of olanzapine and betahistine co-
treatment on attenuating olanzapine-induced weight gain in the rat brain using both drug-
naïve and chronic animal models [64, 65, 75]. In detail, the study using olanzapine-naïve rats 
with 2 weeks’ treatment found that co-treatment of O+B reversed the enhanced H1R and 
AMPK expression induced by olanzapine treatment (Figure 2B) [64]. In addition, the O+B 
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co-treatment decreased the pAMPKα/AMPKα ratio (compared with olanzapine only 
treatment), which was positively correlated with total food intake and H1R expression [64]. 
These findings were confirmed in the chronic repeated olanzapine-treatment rat model; the 
olanzapine-only treatment increased hypothalamic H1R, pAMPKα and AMPKα expression, 
as well as AMPK/pAMPK changes correlated with body weight gain, hyperphagia and 
feeding efficiency [65] (Figure 3B). They are also confirmed by another study in which acute 
ICV injection of FMPH (an H1R agonist) reduced olanzapine-induced hyperphagia [56]. 
Since acute ICV injection of FMPH significantly reduced the olanzapine-induced enhanced 
AMPKα levels [56], the effect of co-treatment with betahistine in reversing 
AMPKα/pAMPKα signalling is through activation of the H1Rs (summarised in Figure 1). 
 
It has been revealed that co-treatment with betahistine attenuates the elevated hypothalamic 
NPY mRNA expression induced by olanzapine in the mediobasal hypothalamus (including 
the Arc) (Figure 2B) [64]. Moreover, AMPK phosphorylation could be promoted by 
stimulating orexigenic hormones such as NPY and AgRP [181]. Since there are synaptic 
interactions between NPY afferents and histamine neurons, and the H3R antagonist 
suppresses NPY induced feeding [182], it is possible that co-treatment with betahistine may 
activate histamine H3R to inhibit olanzapine-induced hyperphagia by suppressing NPY 
(summarised in Figure 1). 
 
It is very interesting that although olanzapine administration decreased the POMC mRNA 
level, that level was not affected by O+B co-treatment in both betahistine animal studies 
(Figure 2B & 3B) [64, 65], which indicated that betahistine attenuation of olanzapine-induced 
weight gain was not via the POMC pathway [64, 65]. The result was consistent with previous 
reports that hypothalamic H1R is independent of the POMC-melanocortin 4 receptor pathway 
in regulation of food intake and body weight [183]; instead, hypothalamic POMC neurons are 
regulated by 5-HT2CR  (summarised in Figure 1).  
 
In addition, UCP1 and PGC-1α protein levels (biomarkers for thermogenesis) in brown 
adipose tissue (BAT) were decreased in rats with drug treatment which indicated a decrease 
in thermogenesis [65] (Figure 3B). Chronic co-treatment with betahistine also reversed the 
attenuated BAT UCP1 and PGC-1α expressions, which illustrated that the two biomarkers of 
thermogenesis were involved in the decreased energy expenditure and increased weight gain 
induced by chronic olanzapine treatment [65]. Furthermore, the negative correlation between 
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hypothalamic pAMPKα, and BAT UCP1 and PGC-1α levels, is in line with the previous 
report about hypothalamic AMPK modulating BAT thermogenesis, and UCP1 and PGC-1α 
expression [184-187]. 
 
Overall, the results from the acute experiment suggested that co-treatment with betahistine 
may reverse olanzapine induced body weight gain via the H1R-NPY and H1R-pAMPKα 
pathways (Figure 2B; summarised in Figure 1) [64]. The olanzapine induced changes in the 
hypothalamic H1R, pAMPKα, BAT UCP1 and PGC-1α were reversed by chronic co-
treatment of O+B (Figure 3B; summarised in Figure 1) [65]. Therefore, co-treatment with 
betahistine may regulate BAT UCP1 and PGC-1α via the hypothalamic H1R and pAMPKα 
pathway.  
 
Furthermore, olanzapine-only treatment significantly increased NEFA in plasma, sterol 
regulatory element binding protein 1 (SREBP-1) and its target gene expression such as 
peroxisome proliferator-activated receptor-α (PPARα) in the liver, while these changes could 
be ameliorated by O+B co-treatment [75]. The same study also revealed that co-treatment of 
O+B increased the hepatic AMPKα, PPARα and its responsive molecule CPT1A, but 
decreased the SREBP-1 protein expression compared with olanzapine treatment [75]. 
Therefore, the co-treatment with betahistine improvement in olanzapine-induced 
dyslipidaemia is attributed to alteration of the post-transcriptional process of SREBP-1 to 
ameliorate olanzapine-induced lipid accumulation in the liver, as well as the responses of 
lipid-metabolic genes, and activation of the AMPK signalling pathway via action at hepatic 
H1R [75].  
 
7. Co-treatment with betahistine does not affect the efficacy of 
antipsychotics 
Serotonin receptors are G protein coupled receptors such as 5-HT2AR and 5-HT2CR; they play 
a vital role in the therapeutic effects of SGAs and the pathophysiology of schizophrenia [188, 
189].  Studies on 5-HTT gene polymorphism have revealed an association with responses to 
the therapeutic effects of olanzapine and other SGAs [190, 191]. The dopamine receptor, 
especially the D2R, is essential for the therapeutic effect of antipsychotics [192, 193]. There 
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are three main dopaminergic pathways projecting dopaminergic neurons, the mesolimbic 
(from VTA to NAc, involved in positive symptoms of schizophrenia), the mesocortical (from 
VTA to cortex including the PFC and Cg, involved in the negative symptoms and cognitive 
deficits of schizophrenia), as well as the nigrostriatal pathways (from the SN to the CPu), also 
involved in the pathophysiology of schizophrenia and antipsychotic treatment [192, 194]. 
 
A key issue is whether co-treatment with betahistine has an impact on the therapeutic effects 
of antipsychotics. Two studies investigated the effects of olanzapine and betahistine co-
treatment on the 5-HT2AR, 5-HT2CR, 5-HTT, and D2R bindings in the brain regions 
associated with the therapeutic efficacy of antipsychotics, including the PFC, NAcC, NAcS 
and Cg, in both drug-naïve and chronic/repeated olanzapine-treated rats [195, 196]. 
 
It was shown that there was significant reduction of 5-HT2AR binding density by olanzapine 
in various brain regions including the PFC, Cg, NAcC and NAcS [197, 195, 196, 189, 198]. 
More importantly, it was revealed that co-treatment with O+B didn’t influence olanzapine’s 
effect on 5-HT2AR in both short-term/drug-naive and chronic/drug re-exposure studies [195, 
196]. As another target for the therapeutic effects of antipsychotics, the 5-HT2CR could be 
downregulated by SGA treatment including olanzapine [196, 199, 198]. Furthermore, it was 
revealed that O+B co-treatment didn’t interfere with the downregulation effect of 5-HT2CR 
binding density in the PFC, Cg, NAcC and NAcS induced by olanzapine-only administration 
[196]. Except the 5-HT2AR and 5-HT2CR, 5-HTT gene polymorphism studies have revealed 
an association with responses to the therapeutic effects of olanzapine and other SGAs [190, 
191]. In the short-term treatment study, both the olanzapine-only and the O+B co-treatment 
studies significantly attenuated 5-HTT bindings in the SN and VTA of drug-naïve rats [195]. 
Additionally, the chronic study showed that reduced 5-HTT binding density was observed in 
the PFC, Cg, NAcC and NAcS in the olanzapine-only treatment and in the Cg, and in the Cg 
and NAcS by co-treatment with betahistine [196]. Thus, these studies revealed that co-
treatment with betahistine had a similar effect on 5-HTT bindings compared with olanzapine-
only treatment in both studies, although the effect occurred in different brain regions [195, 
196].  
 
Both olanzapine and co-treatment of O+B did not cause any significant changes in D2R 
bindings in any brain regions tested after 2 weeks’ treatment [195]. However, in the chronic 
treatment studies, it was revealed that olanzapine administration upregulated the D2R binding 
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levels in the Cg, NAcC, NAcS and CPu [196], as well as the PFC, CPu and NAc [200]. This 
antipsychotic-induced D2R upregulation could cause “dopaminergic supersensitivity” in 
clinics [201, 193], in which long-term/chronic treatment with antipsychotics could enhance 
vulnerability to psychosis frequently observed after drug withdrawal [201]. Additionally, the 
up-regulation of D2R in the CPu by chronic olanzapine administration is associated with the 
development of EPS [200]. It is interesting that chronic betahistine-only treatment at a higher 
dosage (9.6 mg/kg) significantly decreased D2R binding in the NAc and CPu, while no 
change was observed in short-term treatment at a lower dosage (2.67 mg/kg). This difference 
is possibly attributable to both the difference in dosage and treatment duration (2.67 mg/kg 
for 2 weeks’ study vs. 9.6 mg/kg for 5 weeks’ study). It is important to note that olanzapine-
elevated D2R binding in the NAc was reversed by co-treatment with betahistine, which 
suggests that co-treatment with betahistine may improve therapeutic effects by preventing the 
“dopaminergic supersensitivity” (vulnerability to psychosis) and EPS caused by chronic 
antipsychotic treatment [196].  
 
Importantly, clinical studies revealed that betahistine is well-tolerated and safe for co-
treatment with olanzapine to schizophrenia patients, with no interference with the therapeutic 
effect of antipsychotic such as improvement of positive systems of schizophrenia and general 
psychopathology [176, 202, 173]. Therefore, betahistine is a safe drug for co-administration 
with olanzapine for mitigating antipsychotic-induced weight gain/obesity, without 
influencing their therapeutic action. 
 
8. Conclusions 
The SGAs are the first line antipsychotics prescribed to treat schizophrenia and other mental 
disorders. However they are associated with troublesome weight gain/obesity side-effects, 
and other metabolic disorders, which may lead to causes of premature death. Therefore, it is 
extremely important to prevent and treat weight gain/obesity induced by SGAs. It has been 
suggested that the histamine H1R, its downstream pathways and associated neuropeptide are 
involved in the SGA-induced weight gain/obesity side-effects [6, 12, 13]. It has been reported 
that betahistine acts as modulator for the histaminergic system through its H1R-agonsitic and 
H3R-antagonsitic properties in the brain [167, 203]. Importantly, both animal studies and 
clinical trials have shown that co-treatment with betahistine is effective to ameliorate 
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olanzapine-induced weight gain, which acts via modulation of the hypothalamic H1R-
AMPKα, NPY, and BAT UCP1-PGC-1α pathways. Furthermore, co-treatment with 
betahistine was effective in ameliorating olanzapine-induced dyslipidaemia via modulation of 
the AMPKα-SREBP-1 and PPARα-dependent pathways in the liver [75]. Therefore, these 
results not only confirm the importance of these pathways in SGA-induced weight 
gain/obesity side-effects, but also implicate the pathways as promising targets for 
pharmacological intervention to reduce the SGA-induced weight gain. On the other hand, it 
has been also reported that co-treatment with betahistine does not affect the key receptor 
binding sites for the therapeutic efficacy of olanzapine at serotonergic 5-HT2AR, 5-HT2CR 
and 5-HTT, which is consistent with clinical reports that betahistine did not influence  
therapeutic efficacy. In addition, chronic betahistine treatment significantly reversed D2R 
binding density enhanced by olanzapine, which suggests further clinical investigations into 
whether co-treatment with betahistine could improve the efficacy of olanzapine by preventing 
“dopaminergic supersensitivity” caused by chronic antipsychotic treatment [195, 196]. 
Overall, in conjunction with previous preclinical and clinical trials in drug-naïve and repeated 
SGA administration subjects [169, 65, 174, 173], it is necessary to conduct further clinical 
trials to investigate the effects of co-treatment with betahistine on reducing olanzapine-
induced weight gain side-effects in schizophrenia patients with chronic and repeated 
antipsychotic treatment. Furthermore, trials of the co-treatment of betahistine with other 
antipsychotics are worth conducting in the future. 
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Figure 1. A proposed mechanism underlying betahistine reducing SGA-induced body 
weight gain/obesity side-effects through regulation of energy intake and expenditure. On 
the one hand, SGAs block the histamine H1 receptors. The H1R blockade by SGAs may cause 
a compensatory upregulation of H1R density in the hypothalamus, and enhance hypothalamic 
AMPK, NPY and AgRP expression. SGAs may downregulate POMC levels through acting 
on 5-HT2CR. On the other hand, SGAs may reduce thermogenesis by attenuating UCP1 and 
PGC-1α expression in BAT, which could also be modulated by hypothalamic H1R-AMPK 
signalling. In addition, decreased energy expenditure could also be due to reduced locomotor 
activity caused by SGA treatment. As an H3R antagonist, betahistine could block H3R, and 
then stimulate histamine release; betahistine (as a H1R agonist) can directly activate H1R that 
may compete with and decrease the H1R antagonist effect of olanzapine. Furthermore, as an 
H3R antagonist, betahistine increases histamine release by blocking presynaptic H3R 
autoreceptors which may augment its direct agonistic effects on H1R. Therefore, betahistine 
may reduce food intake and weight gain caused by antipsychotics, such as olanzapine.  
 
Abbreviations: 5-HT2CR, serotonin 5-HT2C receptor; AgRP, agouti-related peptide; AMPK, 
AMP-activated protein kinase; BAT, brown adipose tissue; H1R, histamine H1 receptor; NPY, 
neuropeptide Y; PGC-1α, peroxisome proliferator-activated receptor gamma coactivator 1-




Figure 2. Effects of 2-week olanzapine and/or betahistine treatment on body weight gain 
and histamine H1 receptor-AMPK, NPY signallings. (A) Cumulative body weight gain in 
female Sprague Dawley rats treated with olanzapine (1 mg/kg, t.i.d.; n=12), betahistine (2.67 
mg/kg, t.i.d.; n=12), co-treatment (O+B; n=12 or control (vehicle; n=12) for 14 days. 
(Adapted from Deng et al., 2012, Journal of Psychopharmacology; 26(9):1271-9). (B) Effects 
of olanzapine and/or betahistine treatment on hypothalamic mRNA expression of H1R, NPY, 
POMC, AgRP and CART.   
 
Abbreviations: AgRP, agouti-related peptide; CART, cocaine- and amphetamine-regulated 
transcript; H1R, histaminergic H1 receptor; NPY, neuropeptide Y; O+B: combined olanzapine 
and betahistine; POMC, pro-opiomelanocortin; t.i.d.: three times daily. *p<0.05, **p<0.01 vs. 















Figure 3. Effects of chronic olanzapine and/or betahistine treatment on body weight 
gain and histamine H1 receptor-AMPK, NPY signallings. (A) The trend of three phases of 
drug administration on the accumulated body weight side-effect. Olanzapine (1 mg/kg, t.i.d.; 
n= 12), betahistine (9.6 mg/kg, t.i.d.; n=12), co-treatment (O+B; n=12) or control (vehicle; 
n=12) for 11 weeks. (¤: control, N: olanzapine, x: betahistine, m: O+B co-treatment). * 
p<0.05, ** p<0.01 vs. control, # p<0.05 vs. olanzapine. (Adapted from Lian et al., 2014, 
PLoS One; 9(8):e104160). (B) Effects of olanzapine and/or betahistine treatment on the 
protein expression of histamine H1R, AMPKα, pAMPKα, POMC and NPY. Abbreviations: 
H1R: H1 receptor, AMPKa: AMPK-activated protein kinase α, pAMPKα: the AMPK 
phosphorylation α and POMC: pro-opiomelanocortin. * p<0.05, ** p<0.01 vs. control; # 
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Olanzapine (PubChem CID: 4585) 
Betahistine (PubChem CID: 68643) 
Risperidone (PubChem CID: 5073) 
Clozapine (PubChem CID: 2818) 
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